Major drug makers such as J&J have been aiming to improve their drug pipelines and expand uses of older drugs to improve their overall profitability.
The deal includes Aragon's androgen receptor antagonist program, which includes the company's lead product candidate--known as ARN-509--for prostate cancer. The treatment is in Phase 2 development. Aragon's other assets will be spun off into a new company in which J&J won't have an ownership stake.
"ARN-509 complements Zytiga and provides the potential for exciting, novel approaches to treat prostate cancer patients," said Peter F. Lebowitz, global therapeutic area head, oncology for J&J's Janssen research and development unit. "Prostate cancer is one of our main areas of focus."